PIPELINE > TRIAL OVERVIEW
Nectin-4 Antibody-Drug Conjugate 1
LY4101174
Dumontet C, et al1; Challita-Eid PM, et al2; Heath EI and Rosenberg JE3; Fares J, et al4
Target
Molecule
Clinical Development
References
- Dumontet C, et al. Nat Rev Drug Discov. 2023;22(8):641-661.
- Challita-Eid PM, et al. Cancer Res. 2016;76(10):3003-3013.
- Heath EI, Rosenberg JE. Nat Rev Urol. 2021;18(2):93-103.
- Fares J, et al. Preclinical characterization of LY4101174, a next-generation antibody drug conjugate (ADC) targeting Nectin-4. Poster presented at: AACR-NCI-EORTC Annual Meeting; October 11-15, 2023; Boston, MA.
For information on trial enrollment, locations, and more, call
1-800-545-5979.
or visit www.clinicaltrials.gov for more information on this trial